Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials

Purpose: Reliable risk estimates of recurrence are necessary to establish optimal postoperative surveillance strategies. The purpose of the present study was to clarify changes in the hazard rate (HR) for tumor recurrence over time in Japanese patients with colon cancer. Methods: Data for 3984 patients from three clinical trials evaluating the benefit of adjuvant chemotherapy for colon cancer were analyzed. Estimated HRs were plotted over time for the entire cohort, as well as for node-positive and node-negative patients separately. The changes in risk were further analyzed according to eight clinical variables, and factors predictive of early (<3 years) and late (>3 years) recurrence were explored using Cox's regression analysis. Results: In node-positive patients, there was a prominent HR peak 0.6 years after surgery, whereas HR remained at consistently low levels in node-negative patients. In node-positive patients, HR decreased steadily until 3 years, after which the decline in HR plateaued. Those with T4 tumors had a prominent HR peak around 1 year, including node-negative patients. The HR for T1/T2 Stage III colon cancers showed a similar pattern as that for T1-T3 node-negative colon cancers. Cox regression analysis revealed that a lack of adjuvant chemotherapy, positive node status, T3/T4 factors, and male gender predict early recurrence, whereas patients with lymph node metastasis, T4 tumors, and a lesser extent of lymph node removal have a higher risk of recurrence 3-4 years after surgery (P<0.05). Conclusion: The present study supports the concept of intensive surveillance during the first 3 years after curative resection. However, a reduction in surveillance intensity may be acceptable for patients with T3 Stage II and T1/T2 Stage III colon cancer.

[1]  D. Sargent,et al.  Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Yoshikawa,et al.  Hazard rate of tumor recurrence over time: A pooled-analysis of three clinical trials with fluoropyrimidine-based adjuvant chemotherapy for colorectal cancer achieved by the Japanese foundation for multidisciplinary treatment of cancer (JFMC) , 2016 .

[3]  K. Sugihara,et al.  Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies , 2016, Expert opinion on pharmacotherapy.

[4]  Y. Kakeji,et al.  Randomized phase III trial of treatment duration for oral uracil and tegafur plus leucovorin as adjuvant chemotherapy for patients with stage IIB/III colon cancer: final results of JFMC33-0502 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  S. Hendren,et al.  Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. , 2015, Diseases of the colon and rectum.

[6]  Nobhojit Roy,et al.  The Global Burden of Cancer 2013. , 2015, JAMA oncology.

[7]  S. Kitano,et al.  Short-Term Surgical Outcomes From a Randomized Controlled Trial to Evaluate Laparoscopic and Open D3 Dissection for Stage II/III Colon Cancer: Japan Clinical Oncology Group Study JCOG 0404 , 2014, Annals of surgery.

[8]  N. Tomita,et al.  S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial) , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Lordick,et al.  Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Meyerhardt,et al.  Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[12]  R. Labianca,et al.  ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Lepage,et al.  Prevalence of patients with colorectal cancer requiring follow-up or active treatment. , 2009, European journal of cancer.

[14]  Mithat Gonen,et al.  Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Xiaomei Ma,et al.  Global Burden of Cancer , 2006, The Yale journal of biology and medicine.

[16]  Y. Ohashi,et al.  Randomized trial of the efficacy of adjuvant chemotherapy for colon cancer with combination therapy incorporating the oral pyrimidine 1-hexylcarbamoyl-5-fluorouracil , 2006, Langenbeck's Archives of Surgery.

[17]  Daniel J Sargent,et al.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Buyse,et al.  Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. Yasutomi,et al.  Postoperative adjuvant chemotherapy with mitomycin C and UFT for curatively resected rectal cancer. Results from the Cooperative Project No.7 Group of the Japanese Foundation for Multidisciplinary Treatment of Cancer , 1998, International Journal of Clinical Oncology.

[20]  Y. Ohashi,et al.  Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-fluorouracil and uracil/tegafur , 2004, International Journal of Clinical Oncology.